New drug targets Hard-to-Treat heart condition

NCT ID NCT07103655

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called mavacamten in 132 people with hypertrophic cardiomyopathy (thick heart muscle) that blocks blood flow in the middle or tip of the heart's main pumping chamber. The goal is to see if mavacamten can reduce the pressure difference across the blockage and improve heart function. Participants will take mavacamten along with standard treatments like beta-blockers or diltiazem.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mavacamten
What this could lead to: If it works, this could provide a new treatment option for a specific type of hypertrophic cardiomyopathy that is hard to treat.
What could go wrong: This is a small, early-phase study (phase 4) with only 132 participants. It may not show clear benefits, and mavacamten can have side effects like heart failure or arrhythmias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY (HCM)

Contacts and locations

Locations

Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.